I-Chia Liu1, Adam L Holtzman1, Ronny L Rotondo2, Daniel J Indelicato1, Sridharan Gururangan3, Robert Cavaliere4, Bridgette Carter5, Christopher G Morris1, Daryoush Tavanaiepour6, Michael S Rutenberg7. 1. Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, 2015 North Jefferson Street, Jacksonville, FL, 32206, USA. 2. Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS, USA. 3. Department of Neurosurgery and the Preston A. Wells Jr. Center for Brain Tumor Therapy, University of Florida College of Medicine, Gainesville, FL, USA. 4. Baptist MD Anderson Cancer Center, Jacksonville, FL, USA. 5. University of Florida Health Proton Therapy Institute, Jacksonville, FL, USA. 6. Department of Neurosurgery, University of Florida College of Medicine Jacksonville, Jacksonville, FL, USA. 7. Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, 2015 North Jefferson Street, Jacksonville, FL, 32206, USA. mrutenberg@floridaproton.org.
Abstract
PURPOSE: We report disease control, survival outcomes, and treatment-related toxicity among adult medulloblastoma patients who received proton craniospinal irradiation (CSI) as part of multimodality therapy. METHODS: We reviewed 20 adults with medulloblastoma (≥ 22 years old) who received postoperative proton CSI ± chemotherapy between 2008 and 2020. Patient, disease, and treatment details and prospectively obtained patient-reported acute CSI toxicities were collected. Acute hematologic data were analyzed. RESULTS: Median age at diagnosis was 27 years; 45% of patients had high-risk disease; 75% received chemotherapy, most (65%) after CSI. Eight (40%) patients received concurrent vincristine with radiotherapy. Median CSI dose was 36GyE with a median tumor bed boost of 54GyE. Median duration of radiotherapy was 44 days. No acute ≥ grade 3 gastrointestinal or hematologic toxicities attributable to CSI occurred. Grade 2 nausea and vomiting affected 25% and 5% of patients, respectively, while 36% developed acute grade 2 hematologic toxicity (36% grade 2 leukopenia and 7% grade 2 neutropenia). Those receiving concurrent chemotherapy with CSI had a 38% rate of grade 2 hematologic toxicity compared to 33% among those not receiving concurrent chemotherapy. Among patients receiving adjuvant chemotherapy (n = 13), 100% completed ≥ 4 cycles and 85% completed all planned cycles. With a median follow-up of 3.1 years, 4-year actuarial local control, disease-free survival, and overall survival rates were 90%, 90%, and 95%, respectively. CONCLUSIONS: Proton CSI in adult medulloblastoma patients is very well tolerated and shows promising disease control and survival outcomes. These data support the standard use of proton CSI for adult medulloblastoma.
PURPOSE: We report disease control, survival outcomes, and treatment-related toxicity among adult medulloblastoma patients who received proton craniospinal irradiation (CSI) as part of multimodality therapy. METHODS: We reviewed 20 adults with medulloblastoma (≥ 22 years old) who received postoperative proton CSI ± chemotherapy between 2008 and 2020. Patient, disease, and treatment details and prospectively obtained patient-reported acute CSI toxicities were collected. Acute hematologic data were analyzed. RESULTS: Median age at diagnosis was 27 years; 45% of patients had high-risk disease; 75% received chemotherapy, most (65%) after CSI. Eight (40%) patients received concurrent vincristine with radiotherapy. Median CSI dose was 36GyE with a median tumor bed boost of 54GyE. Median duration of radiotherapy was 44 days. No acute ≥ grade 3 gastrointestinal or hematologic toxicities attributable to CSI occurred. Grade 2 nausea and vomiting affected 25% and 5% of patients, respectively, while 36% developed acute grade 2 hematologic toxicity (36% grade 2 leukopenia and 7% grade 2 neutropenia). Those receiving concurrent chemotherapy with CSI had a 38% rate of grade 2 hematologic toxicity compared to 33% among those not receiving concurrent chemotherapy. Among patients receiving adjuvant chemotherapy (n = 13), 100% completed ≥ 4 cycles and 85% completed all planned cycles. With a median follow-up of 3.1 years, 4-year actuarial local control, disease-free survival, and overall survival rates were 90%, 90%, and 95%, respectively. CONCLUSIONS: Proton CSI in adult medulloblastoma patients is very well tolerated and shows promising disease control and survival outcomes. These data support the standard use of proton CSI for adult medulloblastoma.
Authors: Marc Remke; Thomas Hielscher; Paul A Northcott; Hendrik Witt; Marina Ryzhova; Andrea Wittmann; Axel Benner; Andreas von Deimling; Wolfram Scheurlen; Arie Perry; Sidney Croul; Andreas E Kulozik; Peter Lichter; Michael D Taylor; Stefan M Pfister; Andrey Korshunov Journal: J Clin Oncol Date: 2011-05-31 Impact factor: 44.544
Authors: Aaron P Brown; Christian L Barney; David R Grosshans; Mary Frances McAleer; John F de Groot; Vinay K Puduvalli; Susan L Tucker; Cody N Crawford; Meena Khan; Soumen Khatua; Mark R Gilbert; Paul D Brown; Anita Mahajan Journal: Int J Radiat Oncol Biol Phys Date: 2013-02-20 Impact factor: 7.038
Authors: J O del Charco; T W Bolek; W M McCollough; B L Maria; A Kedar; R C Braylan; J P Mickle; J M Buatti; N P Mendenhall; R B Marcus Journal: Int J Radiat Oncol Biol Phys Date: 1998-08-01 Impact factor: 7.038
Authors: Dagmar Beier; Martin Proescholdt; Christiane Reinert; Torsten Pietsch; David T W Jones; Stefan M Pfister; Elke Hattingen; Clemens Seidel; Linda Dirven; Ralf Luerding; Jaap Reijneveld; Monika Warmuth-Metz; Matteo Bonsanto; Michael Bremer; Stephanie E Combs; Stefan Rieken; Ulrich Herrlinger; Holger Kuntze; Regine Mayer-Steinacker; Dag Moskopp; Thomas Schneider; Andreas Beringer; Uwe Schlegel; Walter Stummer; Helmut Welker; Astrid Weyerbrock; Frank Paulsen; Stefan Rutkowski; Michael Weller; Wolfgang Wick; Rolf-Dieter Kortmann; Ulrich Bogdahn; Peter Hau Journal: Neuro Oncol Date: 2018-02-19 Impact factor: 12.300
Authors: Carsten Friedrich; André O von Bueren; Katja von Hoff; Robert Kwiecien; Torsten Pietsch; Monika Warmuth-Metz; Peter Hau; Frank Deinlein; Joachim Kuehl; Rolf D Kortmann; Stefan Rutkowski Journal: Eur J Cancer Date: 2012-11-19 Impact factor: 9.162
Authors: Alba A Brandes; Mario Ermani; Pietro Amista; Umberto Basso; Francesca Vastola; Marina Gardiman; Paolo Iuzzolino; Sergio Turazzi; Antonino Rotilio; Lorenzo Volpin; Carlo Mazza; Laura Sainati; Franco Ammannati; Franco Berti Journal: Int J Radiat Oncol Biol Phys Date: 2003-11-01 Impact factor: 7.038
Authors: Enrico Franceschi; Caterina Giannini; Julia Furtner; Kristian W Pajtler; Sofia Asioli; Raphael Guzman; Clemens Seidel; Lidia Gatto; Peter Hau Journal: Cancers (Basel) Date: 2022-07-29 Impact factor: 6.575